PL2564872T3 - Mazindol sam lub w kombinacji z żelazem do leczenia deficytu uwagi/nadpobudliwości - Google Patents

Mazindol sam lub w kombinacji z żelazem do leczenia deficytu uwagi/nadpobudliwości

Info

Publication number
PL2564872T3
PL2564872T3 PL12189703T PL12189703T PL2564872T3 PL 2564872 T3 PL2564872 T3 PL 2564872T3 PL 12189703 T PL12189703 T PL 12189703T PL 12189703 T PL12189703 T PL 12189703T PL 2564872 T3 PL2564872 T3 PL 2564872T3
Authority
PL
Poland
Prior art keywords
mazindol
deficit
attention
alone
iron
Prior art date
Application number
PL12189703T
Other languages
English (en)
Inventor
Eric Konofal
Original Assignee
Nls Pharmaceutics Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nls Pharmaceutics Ag filed Critical Nls Pharmaceutics Ag
Publication of PL2564872T3 publication Critical patent/PL2564872T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL12189703T 2006-04-11 2007-04-11 Mazindol sam lub w kombinacji z żelazem do leczenia deficytu uwagi/nadpobudliwości PL2564872T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR0603197A FR2899476B1 (fr) 2006-04-11 2006-04-11 Association du mazindol dans le traitement du deficit de l'attention/hyperactivite
EP07727980.0A EP2004183B1 (fr) 2006-04-11 2007-04-11 Association du mazindol dans le traitement du deficit de l'attention/hyperactivite
PCT/EP2007/053512 WO2007116076A1 (fr) 2006-04-11 2007-04-11 Association du mazindol dans le traitement du deficit de l'attention/hyperactivite
EP12189703.7A EP2564872B1 (fr) 2006-04-11 2007-04-11 Mazindol en tant que seul principe actif ou en combinaison avec du fer pour le traitement du déficit de l'attention/hyperactivité

Publications (1)

Publication Number Publication Date
PL2564872T3 true PL2564872T3 (pl) 2021-03-08

Family

ID=36791558

Family Applications (2)

Application Number Title Priority Date Filing Date
PL07727980T PL2004183T3 (pl) 2006-04-11 2007-04-11 Kombinacja mazindolu w leczeniu deficytu uwagi/nadpobudliwości
PL12189703T PL2564872T3 (pl) 2006-04-11 2007-04-11 Mazindol sam lub w kombinacji z żelazem do leczenia deficytu uwagi/nadpobudliwości

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL07727980T PL2004183T3 (pl) 2006-04-11 2007-04-11 Kombinacja mazindolu w leczeniu deficytu uwagi/nadpobudliwości

Country Status (16)

Country Link
US (9) US8293779B2 (pl)
EP (2) EP2564872B1 (pl)
JP (2) JP2009533388A (pl)
CN (2) CN104013620A (pl)
AU (1) AU2007235860B2 (pl)
CA (1) CA2648943C (pl)
DK (1) DK2004183T3 (pl)
ES (2) ES2427570T3 (pl)
FR (1) FR2899476B1 (pl)
IL (1) IL194623A (pl)
MA (1) MA30330B1 (pl)
NZ (1) NZ572002A (pl)
PL (2) PL2004183T3 (pl)
PT (1) PT2004183E (pl)
TN (1) TNSN08397A1 (pl)
WO (1) WO2007116076A1 (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2514879C (en) * 2003-01-03 2014-09-16 Shire Laboratories Inc. Two or more enteric materials to regulate drug release
FR2899476B1 (fr) * 2006-04-11 2008-07-04 Assist Publ Hopitaux De Paris Association du mazindol dans le traitement du deficit de l'attention/hyperactivite
US20090318520A1 (en) * 2008-06-20 2009-12-24 Afecta Pharmaceuticals Drive Use of isoindoles for the treatment of neurobehavioral disorders
MX2012006276A (es) * 2009-12-02 2012-07-10 Supernus Pharmaceuticals Inc Metodo de tratamiento de desordenes del snc.
MX344189B (es) * 2010-03-31 2016-12-08 Supernus Pharmaceuticals Inc Formulaciones de mazindol.
CN102671189B (zh) * 2012-05-10 2013-11-20 南京特丰药业股份有限公司 一种蛋白琥珀酸铁增溶方法及其口服溶液制剂
ITMI20131147A1 (it) 2013-07-09 2015-01-10 Biofer Spa Nuova via di somministrazione del ferro, e nuove formulazioni adatte a tale scopo.
EP3426232B1 (en) * 2016-03-09 2021-06-02 NLS Pharmaceutics AG A mazindol ir/sr multilayer tablet and its use for the treatment of attention deficit/hyperactivity disorder (adhd)
WO2017152974A1 (en) 2016-03-09 2017-09-14 Nls-1 Pharma Ag A mazindol ir/sr multilayer tablet and its use for the treatment of attention deficit/hyperactivity disorder (adhd)
WO2019058172A1 (en) 2017-09-07 2019-03-28 Nls-1 Pharma Ag MAZINDOLE TREATMENT FOR HEROID DEPENDENCE AND DISORDER RELATED TO THE USE OF PSYCHOACTIVE SUBSTANCES
CN115607575A (zh) * 2022-09-19 2023-01-17 重庆医科大学 普雷沃氏菌在防治注意缺陷多动障碍中的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4163799A (en) * 1975-06-13 1979-08-07 Union Chimique Continentale U.C.C. Psychostimulant compounds
US4202897A (en) * 1977-07-25 1980-05-13 Sandoz, Inc. Prolactin secretion inhibitors
US4148906A (en) * 1977-12-30 1979-04-10 Platon J. Collipp Growth hormone inhibitors
IT1194359B (it) * 1983-08-01 1988-09-22 Stabil Bioterapico Farmachim Applicazione terapeutica del mazindolo nella malattia di parkinson
US5217987A (en) * 1989-10-30 1993-06-08 Berger Stephen P Dopamine uptake inhibitors in reducing substance abuse and/or craving
US5447948A (en) * 1992-05-07 1995-09-05 Yale University Dopamine and noradrenergic reuptake inhibitors in treatment of schizophrenia
ES2229783T3 (es) * 1998-06-03 2005-04-16 Alza Corporation Dispositivos para proporcionar una terapia faramaceutica prolongada.
JP2002541092A (ja) * 1999-04-06 2002-12-03 ファーマクエスト・リミテッド メチルフェニデートのパルス性送達のための薬学的投薬形態
AU2002243451A1 (en) * 2001-01-02 2002-07-16 Sention, Inc. Use of catecholamine reuptake inhibitors to enhance memory
US20030036555A1 (en) * 2001-08-03 2003-02-20 Boehringer Ingelheim Pharma Kg Pramipexole for the treatment of ADHD
US20030190355A1 (en) * 2002-04-05 2003-10-09 Hermelin Marc S. Modified release minerals
WO2004091546A2 (en) * 2003-03-31 2004-10-28 Euro-Celtique S.A. Central nervous system stimulant and opioid antagonist combinations
EP2314290A1 (fr) * 2003-05-30 2011-04-27 Assistance Publique - Hôpitaux de Paris Utilisation du fer pour le traitement du trouble du déficit de l'attention/hyperactivité chez les enfants
FR2899476B1 (fr) * 2006-04-11 2008-07-04 Assist Publ Hopitaux De Paris Association du mazindol dans le traitement du deficit de l'attention/hyperactivite

Also Published As

Publication number Publication date
DK2004183T3 (da) 2013-09-23
CN101420953A (zh) 2009-04-29
ES2816629T3 (es) 2021-04-05
JP2009533388A (ja) 2009-09-17
PT2004183E (pt) 2013-09-24
AU2007235860A1 (en) 2007-10-18
US20160030394A1 (en) 2016-02-04
MA30330B1 (fr) 2009-04-01
CA2648943C (fr) 2017-10-24
US20110223260A2 (en) 2011-09-15
CN104013620A (zh) 2014-09-03
ES2427570T3 (es) 2013-10-31
US20090136593A1 (en) 2009-05-28
US20110183009A1 (en) 2011-07-28
NZ572002A (en) 2012-03-30
EP2564872A1 (fr) 2013-03-06
US20240108605A1 (en) 2024-04-04
EP2004183B1 (fr) 2013-06-26
EP2004183A1 (fr) 2008-12-24
EP2564872B1 (fr) 2020-06-10
IL194623A0 (en) 2009-08-03
US20170216258A1 (en) 2017-08-03
IL194623A (en) 2015-03-31
WO2007116076A1 (fr) 2007-10-18
PL2004183T3 (pl) 2013-11-29
US20170252325A1 (en) 2017-09-07
TNSN08397A1 (fr) 2010-04-14
CA2648943A1 (fr) 2007-10-18
US8293779B2 (en) 2012-10-23
US20190328714A1 (en) 2019-10-31
JP2013189467A (ja) 2013-09-26
US20210093614A1 (en) 2021-04-01
US20120308668A1 (en) 2012-12-06
AU2007235860B2 (en) 2012-05-24
FR2899476B1 (fr) 2008-07-04
FR2899476A1 (fr) 2007-10-12

Similar Documents

Publication Publication Date Title
PL2564872T3 (pl) Mazindol sam lub w kombinacji z żelazem do leczenia deficytu uwagi/nadpobudliwości
HK1259102A1 (zh) 用於治療微生物病症的amp
HUS1700015I1 (hu) PDGFR-alfa elleni antitest és alkalmazása tumorok kezelésénél
HK1157410A1 (en) Biomarkers for anti-tnf treatment in ulcerative colitis and related disorders
PL2358697T3 (pl) Związki izoindolinowe do zastosowania w leczeniu raka
PT2101731T (pt) Endoxifeno para utilização no tratamento de cancro
BRPI0809272A2 (pt) Compostos de biaril e biheteroaril no tratamento de distúrbios do ferro
GB0506759D0 (en) Combination treatment methods
IL194202A0 (en) Treatment using citrulline
IL205939A (en) Compounds for use in the treatment of lysosomal disorders
EP1880721A4 (en) MEANS FOR IMPROVING CIRCULAR DISORDER
AP2011005611A0 (en) Amide compounds useful in therapy.
GB0607946D0 (en) Mono and combination therapy
GB0607949D0 (en) Mono and combination therapy
HK1151971A1 (en) Compounds for use in the treatment of cancer
ZA200709542B (en) Combination therapy in the treatment of cancer
ZA200809192B (en) Use of strobilurins for treating malfunctions of the iron metabolism
EP2049095A4 (en) MILNACIPRANE FOR THE TREATMENT OF FERTILIZATION ASSOCIATED WITH FIBROMYALGIA SYNDROME
PL2231171T3 (pl) Kompozycje i sposoby zwiększania wchłaniania żelaza
GB0714500D0 (en) composition and treatment
EG25869A (en) Textile treatment composition
EP2118258A4 (en) AGENTS AND METHODS FOR REDUCING CALCIUM
GB0602857D0 (en) The treatment of sialorrhoea
GB0618815D0 (en) 809 - Pseudoephedrine in the treatment of acute migraine
AU309620S (en) Finishing trim